Seagen Stockholders Approve Acquisition By Pfizer For $229 Per Share In Cash; Acquisition Is Expected To Close In Late 2023 Or Early 2024
Portfolio Pulse from Happy Mohamed
Seagen Inc. (NASDAQ:SGEN) stockholders have approved the acquisition by Pfizer for $229 per share in cash. The acquisition is expected to close in late 2023 or early 2024, subject to regulatory approvals and customary closing conditions.
May 30, 2023 | 7:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's acquisition of Seagen for $229 per share in cash has been approved by Seagen stockholders, with the deal expected to close in late 2023 or early 2024.
The approval of the acquisition by Seagen stockholders is a positive development for Pfizer, as it will allow the company to expand its oncology portfolio and potentially accelerate the development and delivery of transformative cancer medicines. This news is likely to have a positive impact on Pfizer's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Seagen stockholders approved the acquisition by Pfizer for $229 per share in cash, with the deal expected to close in late 2023 or early 2024.
The approval of the acquisition by Seagen stockholders is a significant milestone for the company. The acquisition will provide Seagen with additional resources and support from Pfizer, which could help accelerate the development and delivery of transformative cancer medicines. This news is likely to have a positive impact on Seagen's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100